Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.

Barclays raised the firm's price target on PTC Therapeutics to $56 from $45 and keeps an Equal Weight rating on the shares. The company's deal with Novartis is favorable with high upfront payment and ...

Shares of PTC Therapeutics (PTCT) soared 16% Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis (NVS).

On Monday, PTC Therapeutics, Inc.  PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecule...

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.

PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological diso...

On Tuesday, PTC Therapeutics Inc PTCT revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients.

PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it did not meet the main goal in a mid-stage trial.

The U.S. Food and Drug Administration approved PTC Therapeutics' gene therapy that is administered directly in the brain to treat a potential fatal enzyme deficiency disorder, the company said on Wedn...

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Execu...

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall St...

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.76 per share a year ago.

Besides Wall Street's top -and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared duri...

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.